Triglyceride High-Density Lipoprotein Ratios Predict Glycemia-Lowering in Response to Insulin Sensitizing Drugs in Type 2 Diabetes: A Post Hoc Analysis of the BARI 2D
Table 2
Analysis of HbA1c and differences in the response to therapy evaluated on all patients, on patients above goal at baseline (HbA1c > 7.0%).
Categorizations
All
Above goal (baseline HbA1c > 7.0%)
HbA1c difference: IP minus IS Estimate (95% CI)
Homogen tests values
HbA1c difference: IP minus IS Estimate (95% CI)
Homogen tests values
Overall
2204
0.39 (0.31, 0.47)
1308
0.44 (0.32, 0.55)
TG/HDL fixed ratio groups
0.05
0.009
Normal TG/HDL
879
0.29 (0.16, 0.42)
509
0.24 (0.05, 0.43)
Elevated TG/HDL
1325
0.46 (0.35, 0.56)
799
0.56 (0.41, 0.71)
TG/HDL ratio by categories
0.65 (trend: 0.12)
0.18 (trend: 0.01)
TG/HDL < 2
329
0.31 (0.10, 0.52)
188
0.23 (−0.08, 0.55)
TG/HDL ≥ 2 and <3
354
0.30 (0.10, 0.51)
203
0.27 (−0.03, 0.57)
TG/HDL ≥ 3 and <4
344
0.39 (0.18, 0.59)
211
0.35 (0.06, 0.64)
TG/HDL ≥ 4 and <5
224
0.49 (0.23, 0.74)
134
0.50 (0.13, 0.87)
TG/HDL ≥ 5
953
0.44 (0.32, 0.57)
572
0.60 (0.42, 0.78)
Elevated triglyceride/high-density lipoprotein cholesterol (TG/HDL) ratio means having a value of triglyceride (mg/dL) to HDL-cholesterol (mg/dL) that is 3.75 or higher in men or 3.0 or higher in women. All others are considered “normal.” Categories of triglyceride/high-density lipoprotein cholesterol (TG/HDL) ratio, divided arbitrarily into 5 groups, from <2 (least) to ≥5 (most) insulin resistance.
